These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 15800221

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER.
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract] [Full Text] [Related]

  • 6. The pain game.
    Wadman M.
    Nature; 2007 Jul 26; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract] [Full Text] [Related]

  • 7. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS.
    N Engl J Med; 2005 Mar 31; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV, Barnett EM, Randels CL.
    Adv Nurse Pract; 2005 Nov 31; 13(11):48-50. PubMed ID: 16295003
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW, Reiter S, Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie.
    Z Rheumatol; 2005 May 31; 64(4):286-9. PubMed ID: 15909092
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. COX-2 inhibitors and cardiovascular toxicity: a class effect?
    Laible B.
    S D J Med; 2005 Mar 31; 58(3):93-4. PubMed ID: 15794479
    [No Abstract] [Full Text] [Related]

  • 17. Rofecoxib, Merck, and the FDA.
    Villalba L, Witter J.
    N Engl J Med; 2004 Dec 30; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract] [Full Text] [Related]

  • 18. Under surveillance.
    Nat Biotechnol; 2005 Jan 30; 23(1):1. PubMed ID: 15637596
    [No Abstract] [Full Text] [Related]

  • 19. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar 13; 145(11):60. PubMed ID: 12688204
    [No Abstract] [Full Text] [Related]

  • 20. Institutional review boards must conduct safety review.
    Maloney DM.
    Hum Res Rep; 2005 Feb 13; 20(2):3. PubMed ID: 15839005
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.